In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Why a Patient's Experience with a Drug Matters
Patient reported outcomesare often the primary endpoints in FDA approved pain drugs. Andy Smith shares his insights inMednous.
-
PRO Instruments to Improve Endpoints for Antibacterial Drug Trials
Brittany Erana contributes to this article that features theFDA's selection ofICON to validate PRO instruments used to access clinical endpoints in antibacterial drug trials.
-
Cell and Gene Therapies: On Course for Commercial Success?
Rebecca Walker contributes to this PMLiVE article oncell and gene therapies.
-
Market Access 2017: A European Perspective
Ramita Tandon was interviewed in “Market Access 2017: A European Perspective” in the Pharmaceutical Executive. The article discusses how UK and European regulators’ market access plans for 2017 will affect the industry.
-
Medtech Needs Clinical Registries for Pre- and Postmarket Data
Vicki Anastasi share her insights onclinical registries and generating pre- and postmarket datain this interiew in Medical Design and Outsourcing.
-
Precision Medicine and Data Science
In this article Peter Schueler outlines the future ofdrug development and the central role that precision medicinewill play in global healthcare.
-
Real-world Evidence and the ‘Unsticking’ of Health Care Data
Ramita Tandon outlines in this article in Managed Care how Pharma and CROs must set high standards for acceptablereal-world evidenceresearch.
-
The Future of Clinical Trials
In this article Jennifer Byrne discusses thefuture of clinical trials.
-
Preparing for 2026
Vicki Anastasi contributes to this article which looks atvalue-based healthcare, enabled by wearable and electronic health record (EHR) technologies.
-
2016 FDA Guidance Documents You Should Know
Gordon MacFarlane, senior manager of regulatory affairs and Cynthia Nolte, director of regulatory affairs outline the key points, benefits, and challenges of theFDA guidance documents during 2016 for medical device manufacturers.
